

**Dysfonctionnement de la NADPH oxydase des phagocytes dans la granulomatose septique chronique de type X+ Modèle d'étude: les cellules PLB-985 CGD X**

Xing Jun Li

► **To cite this version:**

Xing Jun Li. Dysfonctionnement de la NADPH oxydase des phagocytes dans la granulomatose septique chronique de type X+ Modèle d'étude: les cellules PLB-985 CGD X. Sciences du Vivant [q-bio]. Université Joseph-Fourier - Grenoble I, 2005. Français. tel-00010978

**HAL Id: tel-00010978**

**<https://tel.archives-ouvertes.fr/tel-00010978>**

Submitted on 28 Dec 2005

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**UNIVERSITE JOSEPH FOURIER-GRENOBLE 1**  
**SCIENCES & GEOGRAPHIE**

N°

## **THESE**

**Pour obtenir le grade de**  
**DOCTEUR DE L'UNIVERSITE JOSEPH FOURIER-GRENOBLE 1**  
**Discipline : Biologie**

**Soutenue publiquement le 29 Septembre 2005 par**

***Xing Jun LI***

Dysfonctionnement de la NADPH oxydase des phagocytes dans la  
granulomatose septique chronique de type X<sup>+</sup>  
Modèle d'étude : les cellules PLB-985 CGD X

### **COMPOSITION DU JURY**

<b>Professeur Philippe Gaudin</b>	<b>Président</b>
<b>Professeur Nicolas Demaurex</b>	<b>Rapporteur</b>
<b>Docteur Jamel El Benna</b>	<b>Rapporteur</b>
<b>Docteur Franck Fieschi</b>	<b>Examineur</b>
<b>Professeur Guan Xiang Qian</b>	<b>Examineur</b>
<b>Docteur Marie José Stasia</b>	<b>Co-Directeur de thèse</b>
<b>Professeur Françoise Morel</b>	<b>Directeur de thèse</b>

Thèse préparée au sein du Groupe de Recherche et d'Etude du Processus Inflammatoire

GREPI EA 2938 / CHU Grenoble

## Remerciements

Ce travail a été réalisé au sein du GREPI sous la responsabilité de Madame le Docteur Marie José Stasia. Je la remercie chaleureusement pour son investissement professionnel et personnel dans le cadre de mon travail. Durant ces trois années, elle a su me faire bénéficier de sa compétence.

Je remercie Monsieur le Professeur Philippe Gaudin sans qui cette thèse n'aurait pas pu exister. Son soutien tant financier qu'humain m'a permis de mener à bien ce travail. Enfin, je veux le remercier d'avoir accepté la Présidence de mon jury de thèse.

Je remercie très sincèrement Madame le Professeur Françoise Morel pour m'avoir accueilli au sein de son laboratoire. Elle a su me transmettre son savoir ainsi que la maturité nécessaire pour poursuivre ce travail.

Je remercie Monsieur le Professeur Nicolas Demaurex d'avoir accepté d'être membre de mon jury de thèse et pour le début de collaboration qu'il a bien voulu établir.

Je remercie très sincèrement Monsieur le Docteur Jamel El Benna pour avoir accepté de participer à ce jury de ma thèse.

A Monsieur le Docteur Franck Fieschi, je tiens ici à exprimer ma gratitude pour l'honneur qu'il me fait en acceptant d'être membre du jury de ma thèse. J'ai particulièrement apprécié le travail que nous avons réalisé ensemble.

Un grand merci à Monsieur le Docteur Didier Grunwald et Monsieur le Docteur Jacques Mathieu pour avoir réalisé les expériences de microscopie confocale ainsi que le tri cellulaire de nos clones.

Un grand merci à Monsieur le Professeur Arthur Hadjian, Marie Hélène Paclet, Yannick Campion, Rachel Tetaz, Emilie Pez, Michèle Guillot et Elisabeth Maquet pour leurs aides et leurs conseils amicaux.

Enfin je remercie très sincèrement l'ensemble de l'équipe des chercheurs du GREPI et de les membres de l'unité fonctionnelle d'Enzymologie, pour leur soutien et leur attention à mon égard.

# Contents

	Pages
<b><u>List of the abbreviations</u></b>	1
<b><u>Summary</u></b>	3
<b><u>Introduction</u></b>	5
<i>En anglais</i>	
<b>1. Bacterial killing mechanism</b>	5
1.1 Reactive oxygen species production (ROS)	5
1.2 Electron transfer and compensation of charge mechanism	7
<b>2. NADPH oxidase</b>	8
2.1 Cytochrome <i>b</i> <sub>558</sub>	8
2.2 Cytosolic components of NADPH oxidase	11
▶ P47 <i>phox</i> (NCF1, neutrophil cytosolic factor 1; NoxO2)	11
▶ P67 <i>phox</i> (NCF2, neutrophil cytosolic factor 2; NoxA2)	13
▶ Rac	13
▶ P40 <i>phox</i>	14
2.3 Rap1A	14
<b>3. Gp91<i>phox</i> (β-subunit, Nox2)</b>	15
3.1 Haem-binding site	15
3.2 FAD-binding site	16
3.3 NADPH-binding site	17
3.4 Glycosylation and maturation	19
3.5 Proton channel	20
3.6 Homologues of Nox2	20
▶ Nox-2S	23
<b>4. Activation and assembly of NADPH oxides</b>	23
4.1 NADPH oxidase assembly during activation	25
4.1.1 <i>Interaction between cytosolic components</i>	25
4.1.2 <i>Interaction between cytosolic factors and cytochrome <i>b</i><sub>558</sub></i>	26
▶ p47 <i>phox</i> with cytochrome <i>b</i> <sub>558</sub>	26
▶ P67 <i>phox</i> with cytochrome <i>b</i> <sub>558</sub>	27
4.2 Interaction between oxidase cytosolic components and membrane lipids	28
<b>5. Chronic granulomatous disease (CGD)</b>	29

1.1 Autosomal CGD (A-CGD)	30
1.2 X-CGD	31
<b>2. Cellular models</b>	36
<b>3. The objective of our work</b>	44
<i>En français</i>	46
<b>1. La production de dérivés toxiques de l'oxygène (ROS)</b>	46
<b>2. NADPH oxidase</b>	47
2.1 Le Cytochrome <i>b</i> <sub>558</sub>	47
2.2 Facteurs cytosoliques	49
2.3 Rap1A	50
<b>3. La granulomatose septique chronique (CGD)</b>	50
3.1 CGD X	50
3.2 CGD AR	51
<b>4. Modèles cellulaires d'étude du complexe oxydase</b>	52
4.1 Les lymphocytes B immortalisés par le virus d'Esptein-Barr (LB-EBV)	52
4.2 Les cellules K562	52
4.3 Les cellules CD34 <sup>+</sup>	52
4.4 Les cellules PLB-985	52
4.5 Les cellules fibroblastiques	53
<b>5. Objectifs du travail</b>	53
<b><u>Results</u></b>	56
<i>Chapter 1: Functional analysis of two-amino acid substitutions in gp91<sup>phox</sup> in a patient with X-linked flavocytochrome b<sub>558</sub>-positive chronic granulomatous disease by means of transgenic PLB-985 cells</i>	57
<b>Résumé en français</b>	57
<b>Résumé en anglais</b>	59
▶ Background	59
▶ Construction of gp91 <sup>phox</sup> transfected PLB-985 cells	59
▶ Detection of NADPH oxidase activity in transfected PLB-985 cells	60
▶ Study of NADPH oxidase assembly in transfected PLB-985 cells	61
▶ Analysis of the 3D-model of the cytosolic C-terminal of gp91 <sup>phox</sup>	62
<b>Article 1</b>	63
<i>Chapter 2: Crucial role of two potential cytosolic regions of Nox2</i>	73

–<sup>191</sup>TSSTKTIRRS<sup>200</sup> and <sup>484</sup>DESQANHFAVHHDEEKD<sup>500</sup>

–on NADPH oxidase activation

<b>Résumé en français</b>	73
<b>Résumé en anglais</b>	76
▶ Background	76
▶ General methodology to obtain the mutant gp91 <sup>phox</sup> PLB-985 cells and to study the impact of each mutation on NADPH oxidase activity and complex assembly	77
▶ Validity of the approach	79
▶ Role of the D loop region of Nox2 and Nox1, Nox3 and Nox4	79
▶ Role of the C-terminal $\alpha$ -helical loop of Nox2	80
<b>Article 2</b>	81
<b>Chapter 3: <i>Leu505 of neutrophil Nox2 is crucial in the NADPH binding process during NADPH oxidase activation</i></b>	93
<b>Résumé en français</b>	93
<b>Résumé en anglais</b>	97
▶ Background	97
▶ The reconstitution and functional study of Leu505Arg X <sup>+</sup> -CGD in the X-CGD PLB-985 cell line	98
▶ Determination of the turn over and the K <sub>m</sub> for NADPH of the WT and Leu505Arg Nox2 cytochrome <i>b</i> <sub>558</sub>	98
▶ Effect of increasing amount of p67 <sup>phox</sup> on NADPH oxidase activity reconstituted in a simplified cell free system assay	99
▶ Analysis of the Leu505 position in the 3D model of the cytosolic C-terminal region of gp91 <sup>phox</sup>	99
<b>Article 3</b>	101
<b>Chapter 4: <i>Study of the cytochrome <i>b</i><sub>558</sub> biosynthesis defect in an X<sup>-</sup> CGD case (S193F Nox2) reproduced in X-CGD PLB-985 and COS-7 cell lines</i></b>	134
<b>Résumé en français</b>	134
<b>Résumé en anglais</b>	136
1. Background	136
2. Study of the biosynthesis of S193F mutated Nox2-cytochrome <i>b</i> <sub>558</sub>	137

1.1 Strategy	137
1.2 Results and discussion	137
▶ S193F Nox2 mRNA amount in X-CGD PLB-985 and COS-7 cells	137
▶ S193F Nox2 amount in X-CGD PLB-985 and COS-7 cells	138
▶ Detection of H <sub>2</sub> O <sub>2</sub> production in the intact cells	140
<b><u>Conclusion and perspectives</u></b>	142
<b>En français</b>	143
<b>En anglais</b>	148
<b><u>References</u></b>	153

## List of the abbreviations

bp	base pair
cDNA	complementary deoxyribonucleic acid
CGD	chronic granulomatous disease
CSF	cell-free system
DFP	diisopropylfluorophosphate
DMF	dimethylformamide
DNA	deoxyribonucleic acid
EDTA	ethylenediaminetetraacetic acid
FACS	flow cytometry
FAD	flavin adenine dinucleotide
fMLP	formyl-methionyl-leucyl-phenylalanine
FNR	ferredoxin-NADP <sup>+</sup> reductase
GST	glutathione S-transferase
GTP $\gamma$ S	guanosine 5'-3- <i>O</i> -(thio) triphosphate
H <sub>2</sub> O <sub>2</sub>	hydrogen peroxide
HRPO	horse-radish peroxidase
INT	iodonitrotetrazolium
K <sub>m</sub>	constant of Michaélis-Menten
mAb	monoclonal antibody
MPO	myeloperoxidase
mRNA	messenger ribonucleic acid
MW	molecular weight
NAD(P)H	Reduced form of nicotinamide-adenine dinucleotide (phosphate)
O <sub>2</sub> <sup>-</sup>	superoxide anion
PBS	phosphate-buffered saline
PCR	polymerase chain reaction
Phox	phagocyte oxidase
PKC	protein kinase C
PMA	phorbol 12-myristate 13-acetate
PMN	polymorphonuclear neutrophils
PMSF	phenylmethyl sulfonyl fluoride
GDI	GDP dissociation inhibitor
RLU	relative luminescence unit
ROS	reactive oxygen species
RP	recombinant protein
SDS	sodium dodecyl sulfate
SDS-PAGE	SDS-polyacrylamide gel electrophoresis
SOD	superoxide dismutase
STZ	serum-treated zymosan
TLCK	tosyl-L-lysine chloromethyl ketone
WT	wild-type



## Summary

Chronic granulomatous disease (CGD) is a rare immuno-deficiency syndrome in which phagocytes lack NADPH oxidase activity. The most common form resulted from mutations in the *CYBB* gene encoding gp91<sup>phox</sup> or Nox2, which is the redox center of the oxidase complex. Very few mutations, referred as X<sup>+</sup>-CGD, led to a normal expression of gp91<sup>phox</sup> with a defective oxidase activity. X<sup>-</sup>-CGD is another rare variant, characterized by a diminished gp91<sup>phox</sup> expression with a weak or absent oxidase activity. The study of these rare variants is useful to establish relationships between a sequence of gp91<sup>phox</sup> and a specific function. The X-CGD PLB-985 cellular model, in which the *CYBB* gene encoding gp91<sup>phox</sup> was interrupted, exhibits an X<sup>0</sup>-CGD phenotype (Zhen et al. 1993).

Mutagenesis approach and stable transfection in X-CGD PLB-985 cells were used to study the defective molecular mechanisms of three X91<sup>+</sup>-CGD mutations, one X91<sup>-</sup>-CGD mutation, and the structure-function analysis of two essential domains of gp91<sup>phox</sup>. WT-Nox2 transfected PLB-985 cells exhibited the same oxidase activity as the original WT PLB-985 cells. Phenotypes of all the studied X<sup>+</sup> or X<sup>-</sup>-CGD were the same as those of the neutrophils from the patients.

The impact of an X<sup>+</sup>-CGD double mutation **His303Asn/Pro304Arg** and of its each mutation on NADPH oxidase functions was carefully dissected in this cellular model. Although the His303Asn mutation has a more severe inhibitory effect on NADPH oxidase assembly and activity than the Pro304Arg mutation, neither mutation can be considered as a polymorphism. **Leu505Arg** mutation originated from a second X<sup>+</sup>-CGD was supposed to be located in the potential adenine-binding site (<sup>504</sup>**GLKQ**<sup>507</sup>). According to the Taylor's 3D model of the C-terminus of Nox2 (Taylor et al. 1996), this mutation is localized at the end of an  $\alpha$ -helical loop, a potential cytosolic factors binding site which could regulate the NADPH access to its binding site. In a simplified cell-free system using purified mutated cytochrome *b*<sub>558</sub>, this mutation diminished the affinity for NADPH and NADH ( $K_m$ -mutant=3 $\times$  $K_m$ -WT). In optimal conditions, this system needs much more p67<sup>phox</sup> to reach the maximal turn over of the oxidase. Leu505Arg mutation seems to alter the structure of  $\alpha$ -helical loop affecting the p67<sup>phox</sup> binding and the NADPH access to its binding site. However no evidence was found for a direct binding of Leu<sup>505</sup> to NADPH. The study of a third X<sup>+</sup>-CGD case due to an **Asp500Gly** mutation in the same  $\alpha$ -helical loop and reproduced in the X-CGD PLB-985 cell model, pointed out the importance of this region on assembly process and electron transfer from NADPH to FAD.

The crucial role of two potential cytosolic domains of gp91<sup>phox</sup> <sup>191</sup>**TSSTKTIRRS**<sup>200</sup> (D-loop) and <sup>484</sup>**DESQANHFVHHDEEKD**<sup>500</sup> ( $\alpha$ -helical loop) were investigated using the same cellular model as above. The RR9192EE-gp91<sup>phox</sup> mutation, known to inhibit oxidase activity and oxidase assembly, was used to validate the methodology (Biberstine-Kinkade et al. 1999). We found that the charged residues in the D-loop (Lys<sup>195</sup>, Arg<sup>198</sup>, Arg<sup>199</sup>) are essential to maintain oxidase activity, but are not involved in oxidase assembly process nor in electron transfer from NADPH to FAD. The same region of Nox1/3/4 is totally functional for oxidase activity, suggesting the existence of a common mechanism underlying the activation of Nox family. Two super-mutants (R199Q, D-loop<sub>Nox4</sub>) were observed to produce more H<sub>2</sub>O<sub>2</sub> activated by PMA or fMLP. The charged residues (Asp<sup>484</sup>, His<sup>490</sup>, Asp<sup>500</sup>) in the C-terminal region (residues 484-500) are essential to support oxidase activity, the oxidase complex assembly, and electron transfer from NADPH to FAD.

Finally an X<sup>-</sup>-CGD case (Ser193Phe) reproduced in the X-CGD PLB-985 cellular model demonstrated that the low cytochrome *b*<sub>558</sub> synthesis was related to a defect in glycosylation process of gp91<sup>phox</sup>.

*Key words:* X<sup>+/-</sup>-CGD, gp91<sup>phox</sup> or Nox2, cytochrome *b*<sub>558</sub>, NADPH oxidase, X-CGD PLB-985 cells